Association of TP53 mutation status with clinical outcomes stratified by sensitive and non sensitive EGFR mutation, in non-small cell lung cancer (NSCLC).

e19076 Background: EGFR mutations (MT) located on exons 19 and 21confer a better prognosis and survival due to their sensitivity to tyrosine kinase inhibitors (TKIs) compared to exon 18 and 20 MTs. The relationship of these MTs to TP53 status and the impact of their co-existence on survival remains unclear. Methods: We conducted a retrospective analysis of Stage IV NSCLC pts treated at the Abramson Cancer Center with established EGFR and TP53 MT status using gene sequencing obtained through our Center for Personalized Diagnostics. Overall Survival (OS) and Progression Free Survival (PFS) were determined for the p53 MT and wild type (WT) cohorts in TKI sensitive (exon 19, 21;SEN) and TKI non-sensitive (exon 18, 20, non- SEN) EGFR MT cohorts Results: Of 51 pts analyzed, there were 37 SEN and 14 non- SEN pts; 38 had TP53 MT and 13 were p53 WT pts. TP53 MT and WT groups were similar for median age (67 vs. 63 yrs), PS (90% ECOG 0-1), smoking status (47% vs. 46% smokers) and T790M status (16% vs. 23%) and femal...